Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.
Location: United States, North Carolina
Employees: 1-10
Total raised: $30M
Founded date: 2020
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.04.2022 | Series B | $30M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 04.04.2022 | Incyclix Bio Raises $30M in Series B Financing | Incyclix Bio, a Reserch Thriangle Park, NC-based cell cycle control company, raised $30M in Series B... | finsmes.co... |